Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: April 20, 2006
- Previous Holding: 17,492,587 ADRs
- New Holding: 17,465,905 ADRs
- Transaction Price: $52.29
- Net Change: Decrease of 26,682 ADRs
This change resulted from a movement in the fund. The Plan is a discretionary fund for employees and former employees. Directors Dr. J.P. Garnier and Dr. T. Yamada are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding director and connected person interests.
Investor Verification Points
- Verify the impact of the 26,682 ADR reduction on the total beneficial ownership of the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the specific nature of the "movement in the fund" that triggered the share count adjustment.
- Review the broader context of Director Dr. J.P. Garnier and Dr. T. Yamada's interests to ensure full compliance with disclosure rules.